These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 21635951)
1. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? Yamagishi S; Matsui T Pharmacol Res; 2011 Sep; 64(3):187-94. PubMed ID: 21635951 [TBL] [Abstract][Full Text] [Related]
2. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. Yamagishi S; Ueda S; Okuda S Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960 [TBL] [Abstract][Full Text] [Related]
3. Role of Asymmetrical Dimethylarginine in Diabetic Microvascular Complications. Du MR; Ju GX; Li NS; Jiang JL J Cardiovasc Pharmacol; 2016 Oct; 68(4):322-326. PubMed ID: 27760067 [TBL] [Abstract][Full Text] [Related]
4. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Yamagishi S; Ueda S; Nakamura K; Matsui T; Okuda S Curr Pharm Des; 2008; 14(25):2613-8. PubMed ID: 18991678 [TBL] [Abstract][Full Text] [Related]
5. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953 [TBL] [Abstract][Full Text] [Related]
6. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. Guo X; Xing Y; Jin W Front Endocrinol (Lausanne); 2023; 14():1183586. PubMed ID: 37152974 [TBL] [Abstract][Full Text] [Related]
7. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion. Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305 [TBL] [Abstract][Full Text] [Related]
8. Peroxynitrite plays a key role in glomerular lesions in diabetic rats. Xiao H; Li Y; Qi J; Wang H; Liu K J Nephrol; 2009; 22(6):800-8. PubMed ID: 19967660 [TBL] [Abstract][Full Text] [Related]
9. [Role of free radicals and reactive nitrogen species in the late complications of diabetes mellitus in rats]. Stadler K; Jenei V; von Bölcsházy G; Somogyi A; Jakus J Orv Hetil; 2004 May; 145(21):1135-40. PubMed ID: 15206194 [TBL] [Abstract][Full Text] [Related]
10. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Satoh M; Fujimoto S; Haruna Y; Arakawa S; Horike H; Komai N; Sasaki T; Tsujioka K; Makino H; Kashihara N Am J Physiol Renal Physiol; 2005 Jun; 288(6):F1144-52. PubMed ID: 15687247 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Pannu R; Singh I Neurochem Int; 2006 Jul; 49(2):170-82. PubMed ID: 16765486 [TBL] [Abstract][Full Text] [Related]
12. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779 [TBL] [Abstract][Full Text] [Related]
13. Nitric oxide in the normal kidney and in patients with diabetic nephropathy. Tessari P J Nephrol; 2015 Jun; 28(3):257-68. PubMed ID: 25216787 [TBL] [Abstract][Full Text] [Related]
14. Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications. Yamagishi S; Matsui T; Nakamura K; Ueda S; Noda Y; Imaizumi T Curr Drug Targets; 2008 Nov; 9(11):1025-9. PubMed ID: 18991613 [TBL] [Abstract][Full Text] [Related]
15. Altered L-arginine/nitric oxide synthase/nitric oxide pathway in the vascular adventitia of rats with sepsis. Jia YX; Pan CS; Yang JH; Liu XH; Yuan WJ; Zhao J; Tang CS; Qi YF Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1202-8. PubMed ID: 17184502 [TBL] [Abstract][Full Text] [Related]
16. Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats. Bojunga J; Dresar-Mayert B; Usadel KH; Kusterer K; Zeuzem S Biochem Biophys Res Commun; 2004 Apr; 316(3):771-80. PubMed ID: 15033467 [TBL] [Abstract][Full Text] [Related]
17. Differential activations of PKC/PKA related to microvasculopathy in diabetic GK rats. Wang H; Jiang YW; Zhang WJ; Xu SQ; Liu HL; Yang WY; Lou JN Am J Physiol Endocrinol Metab; 2012 Jan; 302(2):E173-82. PubMed ID: 21989030 [TBL] [Abstract][Full Text] [Related]
18. Serum apelin and ADMA levels in type 2 diabetics with and without vascular complications. Karakoç A; Sahin A; Polat ES; Aliyev E; Yildirim A; Bakan N; Dokumacioglu E Diabetes Metab Syndr; 2016; 10(2 Suppl 1):S106-9. PubMed ID: 27083312 [TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine regulates the lipopolysaccharide-induced nitric oxide production in macrophages by suppressing the activation of NF-kappaB and iNOS expression. Pekarova M; Kubala L; Martiskova H; Bino L; Twarogova M; Klinke A; Rudolph TK; Kuchtova Z; Kolarova H; Ambrozova G; Kuchta R; Kadlec J; Lojek A Eur J Pharmacol; 2013 Aug; 713(1-3):68-77. PubMed ID: 23665490 [TBL] [Abstract][Full Text] [Related]
20. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. Selley ML J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]